Platinum/taxane-based chemotherapy remains the backbone of ovarian cancer treatment, and previous studies have shown that elevated FAK activation underlies intrinsic and acquired resistance to chemotherapy in residual tumors of patient-derived cells or mouse xenograft tumors treated with platinum or taxanes [35]. This evidence concerns the gene PTK2 and ovarian cancer.